港股迎来siRNA领军企业 瑞博生物启动招股

Core Viewpoint - The article highlights the significant potential of Ribobio, a company specializing in siRNA drug development, particularly with its innovative therapies targeting thrombotic diseases and hypertriglyceridemia, as it prepares for its IPO in Hong Kong and aims to capture a leading position in the growing small nucleic acid drug market [2][3][10]. Group 1: Company Overview - Ribobio has focused on small nucleic acid drugs, especially siRNA therapies, for 18 years and has established one of the largest siRNA drug pipelines globally [3][5]. - The company plans to issue approximately 27.5 million shares at a price of HKD 57.97, aiming to raise around HKD 1.59 billion (approximately USD 205 million) during its IPO scheduled for December 31, 2025 [3][5]. Group 2: Product Pipeline - Ribobio's core product, RBD4059, is the world's first siRNA drug for treating thrombotic diseases, currently in Phase 2a clinical trials, with plans to start Phase 2b trials in 2026 [6]. - RBD5044, another product targeting APOC3 for treating hypertriglyceridemia, is in Phase 2 clinical trials and has the potential to capture a share of the over USD 100 billion lipid-lowering drug market [7][8]. Group 3: International Strategy - Ribobio has established research centers in Beijing and Suzhou, China, and a subsidiary in Sweden to facilitate international clinical trials, enhancing its presence in the lucrative European pharmaceutical market [9]. - The company has formed strategic partnerships, including a collaboration with Qilu Pharmaceutical for the development of RBD7022 and with Boehringer Ingelheim for innovative therapies targeting NASH/MASH, with a combined value of USD 2 billion [9]. Group 4: Financial Performance - Ribobio has completed nine rounds of financing, with a valuation reaching CNY 5.02 billion after the latest round in June 2025, indicating strong growth potential [10]. - The company's revenue is projected to grow from nearly zero in 2023 to CNY 143 million in 2024, with a reduction in losses from CNY 142 million in the previous year to CNY 97.8 million in the first half of 2025 [10].